-
04:32:10 PM

CELZ Stock News

09/19/23 8:00 AM
Nasdaq : CELZ
clinical triallow float
Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain
Creative Medical Technology Holdings, Inc., a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced that the U.S. Food and Drug Administration has cleared the Company to proceed with a Phase 1/ 2 clinical trial of StemSpine ® using...
RHEA-AI
positive
06/28/23 8:00 AM
Nasdaq : CELZ
low float
Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements
Previously, on July 8, 2022, Creative Medical Technology had been notified by Nasdaq that the Company was not in compliance with the minimum bid price rule because its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive business days. In order to regain Nasdaq compliance, the Company was required to maintain a minimum closing...
RHEA-AI
positive
05/31/23 8:00 AM
Nasdaq : CELZ
low float
Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform
Creative Medical Technology Holdings, Inc., a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced that it has received confirmation that Greenstone Biosciences Inc. in Palo Alto, CA has successfully developed a human induced...
RHEA-AI
very positive